Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Regend Therapeutics
With
Peking Union Medical College Hospital
RenJi Hospital
Ruijin Hospital
Second Affiliated Hospital of Xiamen Medical College
Age
40–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female, aged between 40 to 75;
Subjects diagnosed with IPF according to guidelines for the diagnosis of idiopathic pulmonary fibrosis 2022 edition;
Subjects with DLCO (measured/predicted value) ≥30% and \<80%, and FVC (measured/predicted value) ≥50% within 3 months prior to screening
Subjects tolerant to bronchofiberscope;
Subjects tolerant to test of lung function;
Subjects able to voluntarily sign the informed consent and cooperate with the completion of pulmonary function tests;
You may not be if
Female subject who is pregnant, nursing, or planning to be pregnant in half a year after using this product (or male subjects planning to have a pregnant spouse);
At the time of screening, subject who is positive in each of treponema pallidum antibody (TP-Ab), human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody test, except the following: (1) Hepatitis B virus carriers (only HBsAg positive, no hepatitis symptoms and signs, all liver function tests are normal); (2) Cured hepatitis C patients with negative result in HCV ribonucleic acid (RNA) test.
Subject with malignant tumors or a history of malignant tumors;
Subject with severe anemia, poorly controlled agranulocytosis and thrombocytopenia at screening;
Subject at risk of suicide or has a history of mental illness or epilepsy at the time of screening;
Subject with severe arrhythmias or atrioventricular block of degree II or above, shown by 12-lead Electrocardiogram (ECG);
Subject who participated in other interventional clinical trials in the past 3 months;
Subject assessed as inappropriate to participate in this clinical trial by investigators.